Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACAM 2000

Drug Profile

ACAM 2000

Alternative Names: ACAM 1000; ACAM2000; Smallpox (vaccinia) live vaccine - Emergent BioSolutions; Smallpox (vaccinia) live vaccine - Sanofi Pasteur Biologics; Smallpox vaccine - Sanofi Pasteur Biologics

Latest Information Update: 27 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acambis
  • Developer Emergent BioSolutions
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Smallpox

Most Recent Events

  • 21 Nov 2017 Registered for Smallpox (Prevention) in Australia (Transdermal)
  • 21 Nov 2017 Registered for Smallpox (Prevention) in Singapore (Transdermal)
  • 20 Nov 2017 The US FDA approves Emergent BioSolutions' supplemental Biologics License Application (sBLA) to manufacture ACAM 2000 in newly-acquired cGMP live viral manufacturing facility in Canton, Massachusetts
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top